ASCAT 2023 | Upcoming novel agents for the treatment of sickle cell disease
In this video, Perla Eleftheriou, MD, MRCP, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, briefly outlines the novel agents which hold potential for the treatment and management of sickle cell disease. This interview took place at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So there is a significant interest, growing interest, in the management of sickle cell disease. So we want to see molecules such as P-selectin inhibitors and adhesion inhibitors and curative treatments, such as gene therapy treatments. But also there is a lot of interest in complement inhibition, so in molecules/drugs which inhibit the complement system, which we know is over active in patients with sickle cell disease...
So there is a significant interest, growing interest, in the management of sickle cell disease. So we want to see molecules such as P-selectin inhibitors and adhesion inhibitors and curative treatments, such as gene therapy treatments. But also there is a lot of interest in complement inhibition, so in molecules/drugs which inhibit the complement system, which we know is over active in patients with sickle cell disease. And so yes, I mean, you know, there is a wealth of different trials going on at the moment, some of them are in a more advanced phase than others and which are looking into tackling different pathophysiology aspects of sickle cell disease.
Read more...
